About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/19/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/19/2021.

High B Value Diffusion and Stroke

Clinicaltrials.gov identifier NCT03923439

Recruitment Status Recruiting

First Posted April 22, 2019

Last update posted December 20, 2019

Study Description

Brief summary:

This study will include 100 stroke patients with significant penumbra at the acute stage and successfully recanalized thanks to thrombectomy, intravenous thrombolysis or spontaneously. Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system. In this project the investigators hypothesize that diffusion MRI at high and ultra-high b-values could be sensitive enough to quantify selective neuronal loss in the rescued penumbra and to study its relationship with the initial hypoperfusion and its impact in terms of clinical recovery.

  • Condition or Disease:Stroke
  • Intervention/Treatment: Device: Multi-b diffusion sequence MRI
  • Phase: N/A
Detailed Description

Thrombectomy has significantly improved the outcome of stroke patients. However, even after successful recanalization residual handicap including post-stroke cognitive and mood disorders impact the quality of life of patients. These symptoms correlate only moderately with the final stroke volume suggesting more widespread dysfunction than what is apparent on standard follow-up MRI. One hypothesis is that the rescued penumbra (i.e.; the tissue showing significant hypoperfusion at the acute stage but that appears normal on conventional imaging at follow up) could exhibit incomplete ischemic injury also known under the term of selective neuronal loss. The concept of selective neuronal loss in the rescued penumbra is admitted based on histological, animal and PET studies but the identification of such a graduation between pan-necrosis and normal tissue is very challenging to capture in vivo with MRI and is typically missed. This study will prospectively include 100 stroke patients. Patients admitted with significant penumbra at the acute stage and successfully recanalized thanks to thrombectomy thrombolysis or spontaneously will be explored at 24h-to-72h and then at 3 months with the multi-b diffusion sequence. The investigators expect to be able to measure significant modifications within the rescued penumbra as compared to contralateral normal brain by using the advanced but also the simplified diffusion metrics. Investigators will test the impact of duration/severity of the initial hypoperfusion and they will explore the clinical relevance especially in terms of cognitive and mood disorders as measured at 3 months.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 100 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Diagnostic
  • Official Title: High B Value Diffusion and Stroke
  • Actual Study Start Date: April 2019
  • Estimated Primary Completion Date: April 2021
  • Estimated Study Completion Date: April 2021
Arms and interventions
Arm Intervention/treatment
Experimental: MRI protocol
For stroke patients, the follow-up MRI (named MRI-2) after successfully recanalized thanks to thrombectomy, intravenous thrombolysis or spontaneously, will be performed between 24h and 72h after recanalization on our new Canon 3T research magnet with high gradient system. Patients will be explored for a follow-up evaluation at 3 months with a final MRI (named MRI-3) that will be performed on the Canon 3T research magnet.
Device: Multi-b diffusion sequence MRI
Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system.
Outcome Measures
  • Primary Outcome Measures: 1. Mean Diffusivity (MD) (in 10-9 m2/s) [ Time Frame: Up to 72 hours ]
    Computation of Mean Diffusivity (MD) metrics (in 10-9 m2/s) including MDlow for b=1000s/mm2 and pseudo-MDhigh for maps calculated from the highest b-values within the rescued penumbra and within normal contralateral symmetric region of the brain
  • 2. Mean Diffusivity (MD) (in 10-9 m2/s) [ Time Frame: 3 month of follow-up. ]
    Computation of Mean Diffusivity (MD) metrics (in 10-9 m2/s) including MDlow for b=1000s/mm2 and pseudo-MDhigh for maps calculated from the highest b-values within the rescued penumbra and within normal contralateral symmetric region of the brain
  • Secondary Outcome Measures: 1. Mean Kurtosis (MK) [ Time Frame: Up to 72 hours ]
    Average of the diffusional kurtosis along all diffusion directions
  • 2. Mean Kurtosis (MK) [ Time Frame: 3 month of follow-up ]
    Average of the diffusional kurtosis along all diffusion directions
  • 3. Mean Diffusivity of the slow component (MDs) [ Time Frame: Up to 72 hours ]
    Mean Diffusivity of the slow component (MDs) within the rescued penumbra and within normal contralateral symmetric region
  • 4. Mean Diffusivity of the slow component (MDs) [ Time Frame: 3 month of follow-up ]
    Mean Diffusivity of the slow component (MDs) within the rescued penumbra and within normal contralateral symmetric region
  • 5. Magnetization Transfert Ratio [ Time Frame: Up to 72 hours ]
    Magnetization Transfert Ratio maps (MTR=(0-Ms)/M0 x100 where M0 and Ms represent the signal intensity with the saturation prepulse off and on, respectively) within the rescued penumbra and within normal contralateral symmetric region of the brain
  • 6. Magnetization Transfert Ratio [ Time Frame: 3 month of follow-up ]
    Magnetization Transfert Ratio maps (MTR=(0-Ms)/M0 x100 where M0 and Ms represent the signal intensity with the saturation prepulse off and on, respectively) within the rescued penumbra and within normal contralateral symmetric region of the brain
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Patients older than 18 years old

- Cerebral infarct or cerebral hypoperfusion with neurological symptoms within the
anterior circulation

- Due to occlusion or stenosis of intracranial carotid artery or its branches and/or
middle cerebral artery (MCA) and/or anterior cerebral artery.

- With acute MRI performed within the first 24h and showing significant penumbra defined
as ratio between the volumes of critically hypoperfused tissue (defined by Tmax>6s)
and the ischemic core (defined by ADC<600 × 10-6 mm2/s) of 1.8 or more, with an absolute difference of 15 mL or more and ischemic core volume of less than 70 mL. - Successful recanalization by thrombectomy (TICI 2b or 2c or 3) and/or by IV thrombolysis (if within the first 4.5h) or spontaneously. - Patient/Legally Authorized Representative has signed the Informed Consent form. Exclusion Criteria: - History of symptomatic cerebral infarct with functional deficit (pre-stroke modified Rankin Scale score ≥1) to measure the impact of the infarct and selective neuronal loss on long-term outcome without being biased by pre-existing deficits. - History of severe cognitive impairment (dementia) or DSMIV axis 1 psychiatric disorders that would confound the neurological evaluations. - Pregnant or breast-feeding women. - Contraindications to MRI.

Contacts and Locations
Contacts

Contact: Thomas TOURDIAS, Pr 05.56.79.56.04 thomas.tourdias@chu-bordeaux.fr

Locations

France
CHU de Bordeaux
Bordeaux

Sponsors and Collaborators

University Hospital, Bordeaux

More Information
  • Responsible Party: University Hospital, Bordeaux
  • ClinicalTrials.gov Identifier: NCT03923439 History of Changes
  • Other Study ID Numbers: CHUBX 2018/58
  • First Posted: April 22, 2019 Key Record Dates
  • Last Update Posted: December 20, 2019
  • Last Verified: December 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by University Hospital, Bordeaux: Stroke
    High b-value diffusion MRI
    Rescued penumbra
    Selective neuronal loss.
  • Additional relevant MeSH terms: Stroke